Onco-Innovations

What Onco-Innovations does

Onco-Innovations Limited is a Canadian clinical-stage oncology company (Cboe Canada: ONCO; OTCQB: ONNVF; Frankfurt: W1H) headquartered in Calgary, Alberta, developing ONC010, a nanoparticle-encapsulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP) — a novel drug class within the DNA Damage Response (DDR) inhibitor space. The technology is built on an exclusive worldwide license from the University of Alberta covering five patents that span PNKP inhibitor chemistry, the proprietary PEO-PBCL (PEO-b-PBz-CL) polymer micelle nanoparticle delivery system, and synthetic lethality applications targeting PTEN- and SHP1-deficient solid tumors. Preclinical data in PTEN-deficient colorectal cancer models showed a more-than-doubled median survival (60 days vs. 23 days untreated) with a favorable toxicity profile, supporting planned first-in-human Phase 1 trials in late 2026, with subsequent expansion into glioblastoma multiforme and ovarian cancer.

The company operates a dual-platform model. Its wholly-owned subsidiary Inka Health Corp. (acquired February 2025) runs the SynoGraph AI causal-inference platform and the PROmAI multimodal AI research program, providing B2B services to global biopharma clients including AstraZeneca (client since September 2024) and GlaxoSmithKline (May 2026 collaboration) on real-world evidence, patient responder identification, and transportability of clinical trial results. The AI arm is augmented by a OneMedNet iRWD integration (Palantir Foundry-powered) and a Kuano quantum/AI drug-discovery pilot for compound optimization. ONC010 development is executed through an integrated CDMO/CRO partner network: Dalton Pharma Services (API manufacturing, 300g scale-up at ~99.3% purity completed June 2026), Nucro-Technics (preclinical/bioanalytical), Nanosoft Polymers (polymer process development), and Avance Clinical (Australian Phase I), supported by a base shelf prospectus filed February 2026 and a planned C$5 million LIFE private placement expected to close on or about July 10, 2026.

Onco-Innovations is pre-revenue on its lead drug asset, with services revenue from Inka Health individually negotiated and not publicly disclosed; the company reported a CAD $9.3 million net loss over the first nine months of its fiscal year while the stock declined approximately 57% year-to-date as of April 2026. Management is led by CEO Thomas O'Shaughnessy (former Deloitte Canada Partner, MSc Oxford), CFO & Corporate Secretary Dave Antony, Chief Medical Officer Dr. Islam Mohamed, and Chief of R&D Stephen M. Novak, supported by a Scientific & Clinical Advisory Board anchored by two Nobel Peace Prize recipients.

Name

Onco-Innovations

Legal name

Onco-Innovations Limited

Website

https://oncoinnovations.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Onco-Innovations is a Canadian clinical-stage oncology company developing ONC010, a nanoparticle-encapsulated PNKP inhibitor for PTEN-deficient solid tumors, with an AI-driven analytics subsidiary (Inka Health / SynoGraph) serving global biopharmaceutical clients.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Oncology Biosimilars (HLAAAHAG)

Keywords

• DNA damage response therapy
• PNKP inhibitor development
• Clinical-stage oncology
• Nanoparticle drug delivery
• AI drug discovery

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Future Drug Sales (ONC010): Pre-revenue clinical-stage oncology company. Future revenue expected from commercial sales of ONC010 (nanoparticle-formulated PNKP inhibitor) following regulatory approval and commercialization, targeting oncology markets for PTEN-deficient solid tumors, with future expansion to GBM (Glioblastoma multiforme) and ovarian cancer.
2. Inka Health AI Analytics Services: Inka Health Corp. (wholly-owned subsidiary) generates revenue through professional services agreements with global biopharmaceutical companies (e.g., AstraZeneca became a client September 23, 2024) for AI-driven real-world evidence analytics, multimodal AI predictive modeling, causal inference research, and PROmAI program collaborations.
3. Data Monetization / RWE Platform Access: Potential revenue from Inka Health's use of OneMedNet's iRWD platform (powered by Palantir Foundry) to deliver real-world data-driven oncology insights, patient responder identification, and indication expansion analytics for biopharma clients.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

Onco-Innovations is a clinical-stage oncology company developing ONC010, a nanoparticle-encapsulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP) intended to prevent DNA repair in cancer cells. Its lead indication is PTEN-deficient metastatic colorectal cancer, with planned expansion to glioblastoma and ovarian cancer, supported by an exclusive worldwide license to the underlying PNKP technology from the University of Alberta. The company also operates Inka Health Corp., a wholly-owned subsidiary providing AI-driven oncology analytics and real-world evidence services to global biopharmaceutical clients via the SynoGraph platform.

Product overview

Onco-Innovations operates a dual-platform architecture combining proprietary drug development with an AI-enabled discovery and analytics platform. Its core drug development offering is built around ONC010, the lead drug candidate and a nanoparticle-encapsulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), supported by the broader PNKP Inhibitor Technology portfolio (PNKPi), the PEO-PBCL polymer micelle drug delivery platform, and the A83B4C63 active pharmaceutical ingredient. These are advancing through IND-enabling studies and CMC scale-up toward First-in-Human clinical trials. Complementing this, the company's wholly-owned subsidiary Inka Health Corp. runs the SynoGraph AI-driven causal inference platform for oncology evidence generation and the PROmAI (Predicting Oncology Outcomes using Multimodal Artificial Intelligence) research program. Together, these offerings form a vertically integrated pipeline from AI-native drug discovery and quantum/structure-based compound optimization (via Kuano) through CMC manufacturing and preclinical development (with Dalton Pharma Services and Nucro-Technics) into clinical translation.

Differentiator

Problem solved

Functional benefit

Brands

• SynoGraph: Causal-inference AI platform owned by subsidiary Inka Health Corp., integrating multimodal medical data (genomics, transcriptomics, proteomics) to identify which cancer patients are most likely to respond to specific treatments and to support precision medicine and clinical trial design.

Products and services

• ONC010
• PNKP Inhibitor Technology (PNKPi platform)
• SynoGraph AI Platform (by Inka Health Corp.)
• PROmAI (Predicting Oncology Outcomes using Multimodal Artificial Intelligence)
• PEO-PBCL Polymer Nanoparticle Delivery Platform (PEO-b-PBz-CL)
• A83B4C63 (ONC010 Active Pharmaceutical Ingredient)

Quantifiable outcome

• Median survival increased from 23 days to 60 days in PTEN-deficient colorectal cancer animal models (more than doubled median survival)
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core, minor and flagship / core.

• Nanosoft PolymerscoreStrategic or Co-development Partner · 24 June 2026Services agreement following non-binding LOI (June 5, 2026) for polymer process development, analytical characterization, formulation optimization, scale-up support, and technology transfer services for ONCO's proprietary PEO-PBCL polymer platform. Supports IND-enabling development and GMP manufacturing readiness. Winston-Salem, NC-based biotechnology-focused polymer manufacturer led by Dr. Xiaobing Xiong (co-inventor of Onco-Innovations' patented nano delivery system).
• BioMedWire (InvestorBrandNetwork)minorGTM or Marketing Partner · 23 June 2026Editorial coverage feature highlighting ONC010 nanoparticle-encapsulated PNKP inhibitor and broader DDR inhibitor market opportunity. Multiple BioMedWire editorial placements in June 2026.
• InvestorBrandNetwork (IBN)minorGTM or Marketing Partner · 2 June 2026Engaged for market awareness, corporate communications, and digital media services including editorial content, press release recap-style coverage, newsletter coverage, social media relations support, podcast-related distribution and syndication. Cost: USD $76,500 through September 30, 2026. Located at 1108 Lavaca Street, Suite 110-IBN, Austin, TX 78701.
• AstraZenecaflagship / coreStrategic or Co-development Partner · 13 May 2026Research collaboration via Inka Health subsidiary under PROmAI program (Predicting Oncology Outcomes using Multimodal Artificial Intelligence). Evaluates AI-based approaches using deidentified molecular, clinical, and imaging datasets to improve prediction of clinical outcomes. AstraZeneca Canada became client of Inka Health on September 23, 2024 (prior to acquisition by Onco-Innovations on February 3, 2025).
• GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 5 May 2026Collaborative research agreement via Inka Health subsidiary to develop real-world data-driven methodologies for improving transportability of oncology clinical trial results across broader patient populations. Includes conceptual framework, literature review, retrospective validation using oncology datasets, and jointly authored scientific manuscripts.
• RDI PartnerscoreImplementation/ SI/ Consulting Partner · 7 April 2026Engagement agreement to support planned Phase I clinical development activities in Australia alongside establishment of wholly-owned Australian subsidiary Onco-Innovations AU Pty. Ltd. (ONCO AU). Aims to leverage Australia's regulatory environment and R&D incentives.
• OneMedNet CorporationcoreTechnology or Integration · 1 April 2026Collaboration granting Inka Health (Onco-Innovations subsidiary) access to OneMedNet's iRWD platform powered by Palantir Foundry for U.S. real-world oncology data. Supports development of ONC010 PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers including patient responder identification and indication expansion beyond metastatic colorectal cancer.
• University of Albertaflagship / coreOEM/ Whitelabel/ Licensing Partner · 25 November 2025Exclusive worldwide licensor of patented PNKP Inhibitor Technology targeting solid tumors. Ongoing research collaboration includes Dr. Michael Weinfeld (Professor of Oncology, Cross Cancer Institute), Dr. Frederick West (Allard Research Chair in Oncology), Dr. Afsaneh Lavasanifar (Professor in Pharmaceutics), Dr. Dennis Hall (Canada Research Chair in Organoboron Chemistry). License relationship underpinning all ONC010 development.
• Dalton Pharma Servicesflagship / coreStrategic or Co-development Partner · 20 November 2025CDMO partner executing API process development, intermediate scale-up activities, polymer platform development, analytical method development, and multi-kilogram non-GMP synthesis of A83B4C63 at FDA-registered and Health Canada-approved facility in Toronto. Delivered successful 300g API scale-up at ~99.3% purity with no detectable residual solvents. Ongoing collaboration since May 2025.
• Kuano Ltd.coreTechnology or Integration · 19 November 2025Pilot project using quantum-based computational methods and AI-enabled approaches to analyze PNKP Inhibitor Technology (ONC010). Delivered molecular modeling findings, refined structural hypothesis for PNKP inhibition, and framework for structure-based optimization. Follow-on work includes quantum-based QSAR modeling, toxicity mapping, and AI-assisted generative compound design.
• MCS Market Communication Service GmbHminorGTM or Marketing Partner · 30 October 2025Engaged for market awareness and corporate communications services including content creation, project management, third-party media distribution, and digital market awareness initiatives via Google Ads and native advertising. Initial €600,000 engagement (Oct 30, 2025) extended by €210,000 through July 30, 2026. Located in Lüdenscheid, Germany.
• Colorectal Cancer CanadaminorGTM or Marketing Partner · 12 September 2025Onco-Innovations (via Inka Health) chairs and leads the fourth roundtable of Colorectal Cancer Canada's Catalysts: Innovating for Tomorrow Series, focused on data innovation and digital trust in oncology. Roundtable chaired by Inka Health Co-Founder Dr. Paul Arora with Dr. Steve Jones, Dr. Winson Cheung, and Alind Gupta as expert speakers.
• Nucro-Technicsflagship / coreStrategic or Co-development Partner · 4 July 2025Toronto-based contract research organization performing preclinical and bioanalytical development services for ONC010 PNKP inhibitor. Developed LC-MS analytical methods, initiated advanced bioanalytical work for non-GLP PK and biodistribution animal model studies. Agreement signed July 2025.
• Avance Clinical Pty LtdcoreImplementation/ SI/ Consulting Partner · 1 July 2025Start-up agreement for clinical development planning in collaboration with Australian Phase I strategy. Supports planned Phase I clinical development activities in Australia.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Exscientia: AI-driven drug discovery company developing precision medicines, including in oncology, using AI/ML-enabled compound design and patient selection. Comparable to the SynoGraph/Inka Health platform approach of integrating AI into oncology drug development.
• Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas including oncology. Comparable to Inka Health's SynoGraph AI platform as an AI-driven oncology discovery competitor, though Recursion operates at much broader scale and across many disease areas.
• Merck & Co. (MSD): Large-cap pharmaceutical company with a major DDR franchise including PARP inhibitors (Lynparza) and broad oncology pipeline. Comparable as a DDR competitor/partner with substantially greater resources and commercial reach, and explicitly named by Onco as a peer in the DDR space.
• Schrödinger, Inc. Computational chemistry and AI-driven drug discovery company with both platform licensing and proprietary drug development in oncology. Comparable to Onco's hybrid model combining a discovery platform (SynoGraph) with internal drug programs (ONC010), and is also a collaborator of Kuano in the quantum-based computational space.
• AstraZeneca: Global biopharmaceutical company with a leading DDR/synthetic-lethality franchise (Lynparza, Truqap, Tagrisso) and a major oncology pipeline. Currently an enterprise client of Inka Health via the PROmAI program, making it both a partner and a peer against whom Onco's DDR asset would compete commercially if approved.

Emerging players

• Kuano Ltd. Quantum-based and AI-enabled computational drug discovery company. Direct technology partner to Onco for PNKP inhibitor design, and a peer in the broader AI/quantum drug-discovery tooling space serving oncology and other indications.
• Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric therapies targeting DDR and oncogenic mutations. Comparable as a small-cap precision oncology biotech pursuing novel mechanism-of-action DDR-related targets, though its target profile and indication breadth differ from Onco's PNKP focus.

Direct peers

• Repare Therapeutics: Clinical-stage oncology company developing synthetic lethality and DNA Damage Response (DDR) precision medicines, including polymerase theta (Polθ) and other DDR targets. Most direct comparable to Onco given shared synthetic-lethality/DDR mechanistic thesis, similar preclinical-to-Phase 1 stage, and similar cap-table profile.
• Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies for cancer, targeting DDR and other oncogenic dependencies. Comparable business model (oncology-focused, synthetic-lethality platform, indication-specific targeting) and similar stage to Onco's ONC010 program.
• Artios Pharma: Clinical-stage biotech developing DDR inhibitors (including DNA polymerase theta and ATM inhibitors) for cancer therapy. Directly comparable mechanism class to Onco's PNKP program, with similar synthetic-lethality positioning and oncology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/onco-innovations

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onco-Innovations